Clicky

ISU Abxis Co. Ltd(086890)

Description: ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy. ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.


Keywords: Cancer Biopharmaceutical Life Sciences Treatment Of Cancer Monoclonal Antibodies Rare Diseases Lipid Storage Disorders Treatment Of Hemophilia Enzyme Replacement Therapy Fabry Disease Gaucher Disease Paroxysmal Nocturnal Hemoglobinuria Hemophilia B Gaucher's Disease Gpiib/Iiia Inhibitors

Home Page: www.abxis.com

Global R&D Center Building C
Seongnam-si, 13488
South Korea
Phone: 82 3 1696 4700


Officers

Name Title
Sang-Ho Park Ph.D. Chief Exec. Officer
Chang-Hoon Choi Exec.
Mr. Heung-Rok Park Exec.
Joon-Young Park Exec.
Mr. Seungho Kim Exec.
Young-Soo Sohn Exec.
Mr. Sung-Ho Choi Exec.
Jin-Chul Shin Exec.
Hyun-Il Kim Exec.
Jae-Heung Lee Exec.

Exchange: KQ

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 5.2516
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks